Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2005
05/06/2005WO2005040355A2 Tao kinase modulators and methods of use
05/06/2005WO2005040345A2 4-azole substituted imidazole compositions useful as inhibitors or c-met receptor tyrosine kinase
05/06/2005WO2005040338A2 Constrained alkaloid immunogens and antibodies and uses thereof
05/06/2005WO2005040247A1 Polymeric composition for drug delivery
05/06/2005WO2005040228A2 Disintegratable films for diagnostic devices
05/06/2005WO2005040189A1 Novel dammarane sapogenins and their use as anti-cancer agents
05/06/2005WO2005040182A1 Novel inhibitor for advanced glycation endproduct formation and aldose reductase inhibitor
05/06/2005WO2005040176A2 Methods for the preparation of {2-[8,9-dioxo-2,6-diaza-bicyclo[5.2.0]-non-1(7)-en-2-yl]ethyl}phosphonic acid and esters thereof
05/06/2005WO2005040174A1 Tetrahydro-furo`3,4-d!dioxole compounds and compositions and method for inhibiting platelet aggregation
05/06/2005WO2005040172A1 Tricyclic proline derivative
05/06/2005WO2005040169A2 Fused heterocyclic compounds as serotonin receptor modulators
05/06/2005WO2005040168A1 Azabenzodiazepines as phosphodiesterase-4 inhibitors
05/06/2005WO2005040163A1 Heterocyclic compounds that block the effects of advanced glycation end products (age)
05/06/2005WO2005040161A1 Biaryl linked hydroxamates: preparation and pharmaceutical applications
05/06/2005WO2005040160A2 Processes for preparation of ziprasidone
05/06/2005WO2005040158A1 1-′(e)-2-(phenyl) ethenyl-4-(arylalkoxy)-oxazole or - thiazole compounds as her-2 tyrosine kinases inhibitors and their use in the treatment of cancer
05/06/2005WO2005040156A1 Azole derivative useful as antifungal agents with reduced interaction with metabolic cytochromes
05/06/2005WO2005040151A1 Pyrazine derivatives and pharmaceutical use thereof
05/06/2005WO2005040150A2 Glutamine fructose-6-phosphate amidotransferase (gfat) inhibitors
05/06/2005WO2005040147A1 Antitumor agent
05/06/2005WO2005040142A1 Novel keto-oxadiazole derivatives as cathepsin inhibitors
05/06/2005WO2005040138A1 Substituted benzylaminoalkylene heterocycles
05/06/2005WO2005040135A1 Antistress drug and medical use thereof
05/06/2005WO2005040134A1 Process for the preparation of amorphous rosuvastatin calcium
05/06/2005WO2005040132A1 Dicationic triaryl analogs as anti-protozoan agents
05/06/2005WO2005040131A1 1,5,7-trisubstituted benzimidazole derivatives and their use for modulating the gabaa receptor complex
05/06/2005WO2005040129A2 Ccr3 receptor antagonists
05/06/2005WO2005040125A1 Quinazoline derivatives for the treatment of herpesviral infections
05/06/2005WO2005040124A1 A polymorphic form of 3-phenylsulfonyl -8-piperazin-1-yl-quinoline
05/06/2005WO2005040121A2 Amides that inhibit vanilloid receptor subtype 1 (vr1) receptor
05/06/2005WO2005040116A2 Indolinone derivatives and their use in treating disease-states such as cancer
05/06/2005WO2005040111A2 Combinatorial library of 3-aryl-1h-indole-2-carboxylic acids
05/06/2005WO2005040109A1 Ligands of melanocortin receptors and compositions and methods related thereto
05/06/2005WO2005040106A1 Thiourea derivative-containing pharmaceutical composition having improved solubility and bioavailability
05/06/2005WO2005040100A1 Tetrahydro-naphthalene and urea derivatives
05/06/2005WO2005040097A1 Resolution of 3-amino alkylnitriles
05/06/2005WO2005040091A1 Aminoalkanol derivatives
05/06/2005WO2005040073A2 Solid phase synthesis of 3-aryl-2- indolylcarboxylic acids
05/06/2005WO2005040045A2 Method for the production of trans- or cis-diammoniumdichlorodihydroxoplatinum (iv) and use thereof for the production of pharmaceutical agent
05/06/2005WO2005039727A1 Extraction process
05/06/2005WO2005039685A1 Transdermal drug delivery method and system
05/06/2005WO2005039645A2 Sp1 and sp3 targeted cancer therapies and therapeutics
05/06/2005WO2005039642A1 Dna delivery with gemini cationic surfactants
05/06/2005WO2005039640A1 Compositions comprising trefoil factor family peptides and/or mucoadhesives and proton pump inhibitor prodrugs
05/06/2005WO2005039639A2 Pharmaceutical composition comprising a selective i1 imidazoline receptor agonist and an angiotensin ii receptor blocker
05/06/2005WO2005039638A2 Therapeutic agent for heart failure comprising an angiotensin ii receptor antagonist and a matrix metalloproteinase inhibitor
05/06/2005WO2005039637A2 Combinations of an aldosterone receptor antagonist, a diuretic and an angiotensin blocker
05/06/2005WO2005039636A1 Agent for potentiating curing effects-enhancing medicinal substance action
05/06/2005WO2005039633A1 Agent for treating leishmania infections
05/06/2005WO2005039629A2 Caspase inhibitors as coating materiel for medical products for inhibiting restenosis
05/06/2005WO2005039626A2 Use of hydroxylated amino acids for treating diabetes
05/06/2005WO2005039619A1 Compositions and methods comprising prostaglandin-related compounds and trefoil factor family peptides for the treatment of glaucoma with reduced hyperemia
05/06/2005WO2005039612A1 Methods and compositions comprising ilex
05/06/2005WO2005039603A1 Combined preparation for treating sepsis
05/06/2005WO2005039602A1 Pharmacologically functional water and use thereof
05/06/2005WO2005039599A1 Matrix metalloprotease inhibitor containing polylactic acid mixture
05/06/2005WO2005039598A1 Method of treating alcoholic liver disease
05/06/2005WO2005039597A2 Immunemodulating oligosaccharides
05/06/2005WO2005039596A1 Silyl phenols for promoting vascular health
05/06/2005WO2005039595A1 Improving or therapeutic agent for disturbances of peripheral circulation, containing cyclophosphamide as active ingredient
05/06/2005WO2005039594A1 Combinations comprising ampa receptor antagonists for the treatment of myopia
05/06/2005WO2005039593A1 Combinations comprising ampa receptor antagonists for the treatment of neuropathic pain
05/06/2005WO2005039592A1 Treatment of inflammatory bowel disease with 2-methylene-19-nor-vitamin d compounds
05/06/2005WO2005039590A1 Non-nucleotide compositions and method for treating pain
05/06/2005WO2005039589A2 Cftr channel modulators
05/06/2005WO2005039588A2 Methods for determining the risk of developing liver and lung toxicity
05/06/2005WO2005039587A1 Heterocycle-substituted pteridine derivatives and their use in therapy
05/06/2005WO2005039586A1 Use of pyridinyl-pyrimidinylamino-benzamide derivatives for the treatment of amyloid related disorders
05/06/2005WO2005039585A1 Methods, compositions, and kits for organ protection during systemic anticancer therapy
05/06/2005WO2005039584A1 Improved antitumoral combinations containing et-743 and a cruciferous and a cruciferous indole compound
05/06/2005WO2005039583A1 METHOD OF TREATING RHEUMATOID ARTHRITIS USING NF-kB INHIBITORS
05/06/2005WO2005039582A1 METHODS OF TREATING ATHEROSCLEROSIS USING NF-kB INHIBITORS
05/06/2005WO2005039581A1 Use of estrogen receptor ligands for the treatment of inflammatory bowel disease
05/06/2005WO2005039580A1 Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an acetylcholinesterase inhibitor
05/06/2005WO2005039579A1 Combination treatment of obesity involving selective cb1-antagonists and lipase inhibitors
05/06/2005WO2005039578A2 Use of a deoxynojirimycin derivative or a pharmaceutically salt thereof
05/06/2005WO2005039577A1 Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pain
05/06/2005WO2005039576A1 Combinations of potassium channel openers and sodium channel inhibitors or active substances influencing sodium channels in order to treat painful conditions
05/06/2005WO2005039575A1 Remedy for hyperlipemia
05/06/2005WO2005039574A1 Therapeutic agent for keratoconjunctive disorder
05/06/2005WO2005039573A2 Biomarkers for the prediction of drug-induced diarrhoea
05/06/2005WO2005039572A1 N-thiazol-2-yl-benzamide derivatives
05/06/2005WO2005039571A1 Therapeutic agent for keratoconjunctiva disorder
05/06/2005WO2005039570A1 TGF-β INFORMATION TRANSFER PATHWAY INHIBITOR
05/06/2005WO2005039569A1 5-substituted 2-(phenylmethyl) thio-4-phenyl-4h-1,2,4-triazole derivatives and related compounds as gaba-agonists for the treatment of urinary incontinence and related diseases
05/06/2005WO2005039568A1 Multiple active agents such as anthelmintics sustained release delivery
05/06/2005WO2005039567A1 Pharmaceutical compositions comprising alpha-2-adrenergics and trefoil factor family peptides
05/06/2005WO2005039566A1 Combination treatment of obesity involving 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity and lipase inhibitors
05/06/2005WO2005039565A1 Combinations of cox and vasopressin inhibitors for the treatment of dismenorrhea
05/06/2005WO2005039564A1 Phthalimide compounds useful as protein kinase inhibitors
05/06/2005WO2005039563A2 Use of neurokinin antagonists in the treatment of urinary incontinence
05/06/2005WO2005039562A1 A use of lancifolide derivatives and the composition comprising the same
05/06/2005WO2005039561A1 Micronized bicyclol and the orally administered controlled release formulation
05/06/2005WO2005039560A1 Use of3-amino chromans or thiocromans for the treatment of prostate cancer
05/06/2005WO2005039559A1 Composition functioning to prevent or mitigate symptom or disease attributable to blood vessel aging
05/06/2005WO2005039558A1 Targeted delivery of therapeutically active compounds
05/06/2005WO2005039557A1 Use of selected amino acid-zinc complexes as anti-malarial
05/06/2005WO2005039556A1 Medicine for preventing and/or treating restenosis or reocclusion after blood circulation restoration
05/06/2005WO2005039555A1 Extended release tablet formulations of venlafaxine
05/06/2005WO2005039554A2 Therapeutic use of methionine for the treatment or prevention of mucositis
1 ... 4698 4699 4700 4701 4702 4703 4704 4705 4706 4707 4708 4709 4710 4711 4712 4713 4714 4715 4716 4717 4718 ... 7860